Screener
AOCI at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Ordinary shares | — | — |
| Non-voting euro deferred shares | 0.1 | 0.1 |
| Capital redemption reserve | 0.5 | 0.5 |
| Additional paid-in capital | 4,243.5 | 4,240.5 |
| Accumulated other comprehensive loss | (651.0) | (568.6) |
| Retained earnings | 939.2 | 646.1 |
| Total shareholders’ equity | 4,532.3 | 4,318.6 |
| Total liabilities and shareholders’ equity | $11,859.6 | $11,659.3 |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's AOCI?
- Jazz Pharmaceuticals (JAZZ) reported AOCI of -$651M in Q1 2026.
- How has Jazz Pharmaceuticals's AOCI changed year-over-year?
- Jazz Pharmaceuticals's AOCI increased by 17.1% year-over-year, from -$785.61M to -$651M.
- What is the long-term trend for Jazz Pharmaceuticals's AOCI?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's AOCI has grown at a 33.4% compound annual growth rate (CAGR), from -$134.35M to -$568.6M.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.
Ask your AI about Jazz Pharmaceuticals's aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude